Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02065596 · ClinicalTrials.gov registry record · Phase 1

Hematopoietic Stem Cell Transplant for Sickle Cell Disease

A Phase 1 study of Sickle Cell Disease and Sickle Cell Anemia, sponsored by Case Comprehensive Cancer Center.

Completed
Registry status
Phase 1
Development phase
4
Enrollment target
1
Study location

NCT02065596: Completed Phase 1 study of Sickle Cell Disease and Sickle Cell Anemia, sponsored by Case Comprehensive Cancer Center.

NCT02065596 is a Phase 1 study of Sickle Cell Disease and Sickle Cell Anemia that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 4 participants, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02065596, a Phase 1 study of Sickle Cell Disease and Sickle Cell Anemia, has completed, sponsored by Case Comprehensive Cancer Center.

COMPLETED
Registry status
Phase 1
Development phase
4 participants
Enrollment target
1
Study location

Study Summary

This is a study of patients with sickle cell disease. It aims to find out if people with sickle cell disease can be cured by changing their immune system before they have blood stem cell transplants. Doctors will give patients a new drug (fludarabine) to see if this drug changes patients immune system and reduces the patient's cells (host) from rejecting donor cells (graft) after the patient gets a Hematopoietic (blood) stem cell transplant.

Primary Outcome

The number of patients with engraftment (as defined as recovery of ANC to 500 cells per cubic mm) compared to the total number of patients treated as a function of the patient's age.

Conditions Studied

Sickle Cell Disease Sickle Cell Anemia SCD

Interventions

  • DRUG Fludarabine
  • PROCEDURE Hematopoietic Stem Cell Transplant (HSCT)

Study Locations (1)

Ohio

  • University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center - Cleveland

Trial Details

FieldValue
Enrollment Target 4 participants
Start Date 2015-10-19
Est. Completion 2023-02-17
Phase Phase 1
Case Comprehensive Cancer Center

407 total trials

What the finished NCT02065596 record still lists

NCT02065596 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (99% lower).

The record links to 3 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 2 interventions - of which Fludarabine is the first listed.

NCT02065596 reports a single indexed study location in Ohio.

Frequently Asked Questions

What is clinical trial NCT02065596 about?

NCT02065596 is a clinical study titled "Hematopoietic Stem Cell Transplant for Sickle Cell Disease". This is a study of patients with sickle cell disease. It aims to find out if people with sickle cell disease can be cured by changing their immune system before they have blood stem cell transplants. Doctors will give patients a new drug (fludarabine) to see if this drug changes patients immune syst...

What is the current status of trial NCT02065596?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2015-10-19. Estimated completion is 2023-02-17.

What conditions does trial NCT02065596 study?

This clinical trial studies the following conditions: Sickle Cell Disease, Sickle Cell Anemia, SCD.

What interventions are being tested in trial NCT02065596?

The interventions under investigation include: Fludarabine (DRUG), Hematopoietic Stem Cell Transplant (HSCT) (PROCEDURE).

Who is sponsoring clinical trial NCT02065596?

This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02065596 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Sickle Cell Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02065596's enrollment target sits among peer trials

4 210th of 213 higher than 3 of 213 other Sickle Cell Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Sickle Cell Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT02065596, the US trial registry maintained by the National Library of Medicine. NCT02065596 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.